Fresenius SE Signs Exclusive Deal with WuXi Biologics to Add Up to 37 Biosimilar Candidates

MT Newswires · 11/02 01:56
01:56 AM EST, 11/02/2026 (MT Newswires) -- Fresenius SE (FRE.F) signed a development agreement with WuXi Biologics to gain exclusive option rights for up to 37 potential biosimilar candidates, according to a Monday release. The partnership could expand the German healthcare company's biosimilars pipeline to up to 66 in the next decade from the existing 29 marketed molecules. The company will have the flexibility to select which biosimilar candidates to develop based on market potential, development risk, and expected returns. Fresenius will retain exclusive global sales rights and full commercial earnings from products developed under the agreement. It will pay WuXi Biologics for development services for each selected biosimilar candidate.